Chemical characterization of high buoyant density proteoglycan accumulated in the affected skin of pretibial myxedema of Graves' disease.
From three patients with pretibial myxedema (PTM) of Graves' disease, a portion of the skin involved was biopsied, analyzed for proteoglycans and the results were compared with those obtained with euthyroid and hyperthyroid subjects without PTM. The tissue specimen was extracted with 4 M guanidine HCl and subjected to subsequent CsCl density gradient centrifugation. Glycosaminoglycan and protein were recovered in the heaviest density fraction in the three specimens obtained from patients with PTM and not from subjects without PTM. From the analysis by Sepharose CL-6B column, glycosaminoglycan was present as a form of proteoglycan because alkaline borohydride treatment released single chain glycosaminoglycan with a molecular weight of 77,000 or 66,000. The digestion with chondroitin ABC lyase revealed that the majority of proteoglycan in the skin tissue was chondroitin sulfate or dermatan sulfate, and heparan sulfate comprised the minor component (14-34%). The rate of proteoglycan biosynthesis was examined by 35S incorporation into glycosaminoglycan's by cultured fibroblasts from PTM and normal skin. Incorporation of 35S into both proteoglycan and single chain glycosaminoglycan was observed in the fibroblasts of PTM patients as well as of those of subjects without PTM, although the rate of synthesis was more pronounced in the former. The rate of synthesis was influenced neither by normal serum or serum from a pretibial myxedema patient. Since proteoglycan accumulation was detected only in the affected skin of PTM patients, the impairment of local degradation and the proteoglycan clearance mechanism may also be involved.
D002500:Centrifugation, Isopycnic; D002809:Chondroitin Sulfates / Q000032:analysis; D006111:Graves Disease / Q000503:physiopathology*; D006497:Heparan Sulfate / Q000032:analysis; D006801:Humans; D008970:Molecular Weight; D009230:Myxedema / Q000503:physiopathology*; D011509:Proteoglycans / Q000032:analysis*; D012871:Skin Diseases / Q000503:physiopathology
D002809:Chondroitin Sulfates; D006497:Heparan Sulfate; D011509:Proteoglycans